GSK's Pandemrix safe for now as European narcolepsy ADR reports rise
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has decided not to restrict the use of GlaxoSmithKline's H1N1 pandemic vaccine, Pandemrix, while it conducts its review into whether there is a possible link to narcolepsy, following its CHMP meeting last week.